AVR Stock Analysis: Anteris Technologies Global | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.029m USD | 12M Return: 193.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 13.5M
Qual. Beats: 0
Rev. Trend: -88.0%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 1.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Anteris Technologies Global Corp. (NASDAQ: AVR) is a structural heart medical device company headquartered in Toowong, Australia, focused on developing and commercializing minimally invasive devices to treat heart valve diseases. Its lead product is the DurAVR transcatheter heart valve system, designed to treat severe aortic stenosis by mimicking the performance of a healthy human aortic valve. The company also develops the ADAPT anti-calcification tissue platform, which prepares xenograft tissue for use as durable bioscaffolds in surgical repair, and the ComASUR delivery system, a balloon-expandable, steerable catheter designed for controlled navigation through the heart anatomy.
The structural heart device market is a high-growth segment within the broader medical device industry, driven by the increasing prevalence of valvular heart disease in aging populations and a long-term shift from open-heart surgery toward transcatheter approaches such as TAVR (transcatheter aortic valve replacement). As a pre-commercial, clinical-stage developer, Anteris is positioned as an emerging challenger to established players in the TAVR space, with its value tied to future clinical trial readouts, regulatory approvals, and successful commercial uptake of the DurAVR system.
- DurAVR FDA breakthrough designation and approval progress
- FIH clinical trial readouts for DurAVR system drive sentiment
- Equity dilution risk as cash burn accelerates pre-revenue
| Net Income: -95.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.29 > 0.02 and ΔFCF/TA 87.96 > 1.0 |
| NWC/Revenue: 14.7k% < 20% (prev 1.55k%; Δ 13.2k% < -1%) |
| CFO/TA -0.29 > 3% & CFO -85.0m > Net Income -95.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 20.93 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.6m) vs 12m ago 0.0% < -2% |
| Gross Margin: 28.25% > 18% (prev 53.05%; Δ -24.79% > 0.5%) |
| Asset Turnover: 1.05% > 50% (prev 4.24%; Δ -3.19% > 0%) |
| Interest Coverage Ratio: -1.28k > 6 (EBIT TTM -94.6m / Interest Expense TTM 74.0k) |
| A: 0.93 (Total Current Assets 286.7m - Total Current Liabilities 13.7m) / Total Assets 294.7m |
| B: -1.34 (Retained Earnings -393.6m / Total Assets 294.7m) |
| C: -0.54 (EBIT TTM -94.6m / Avg Total Assets 176.8m) |
| D: 17.07 (Book Value of Equity 278.4m / Total Liabilities 16.3m) |
| Altman-Z'' = 16.05 = AAA |
| DSRI: 1.65 (Receivables 231k/189k, Revenue 1.85m/2.49m) |
| GMI: 1.88 (GM 53.05% / 28.25%) |
| AQI: 0.15 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 0.74 (Revenue 1.85m / 2.49m) |
| TATA: -0.03 (NI -95.3m - CFO -85.0m) / TA 294.7m) |
| Beneish M = -2.39 (Cap -4..+1) = BBB |
As of July 11, 2026, the stock is trading at USD 9.77 with a total of 695,044 shares traded. Over the past week, the price has changed by -4.59%, over one month by +2.84%, over three months by +72.01% and over the past year by +193.83%.
Current recommended Stop Loss: 9.00 (which is 7.9% or 1.2 ATR below the current price).
Anteris Technologies Global has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy AVR.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.3 | 56.9% |
P/S = 555.8655
P/B = 3.5781
Revenue TTM = 1.85m USD
EBIT TTM = -94.6m USD
EBITDA TTM = -92.9m USD
Long Term Debt = 2.42m USD (estimated: total debt 3.73m - short term 1.31m)
Short Term Debt = 1.31m USD (from shortTermDebt, last quarter)
Debt = 5.34m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.61m
Net Debt = -277.9m USD (calculated: Debt 5.34m - CCE 283.2m)
Enterprise Value = 751.0m USD (1.03b + Debt 5.34m - CCE 283.2m)
Interest Coverage Ratio = -1.28k (Ebit TTM -94.6m / Interest Expense TTM 74.0k)
EV/FCF = -8.66x (Enterprise Value 751.0m / FCF TTM -86.7m)
FCF Yield = -11.54% (FCF TTM -86.7m / Enterprise Value 751.0m)
FCF Margin = -4.68k% (FCF TTM -86.7m / Revenue TTM 1.85m)
Net Margin = -5.15k% (Net Income TTM -95.3m / Revenue TTM 1.85m)
Gross Margin = 28.25% ((Revenue TTM 1.85m - Cost of Revenue TTM 1.33m) / Revenue TTM)
Gross Margin QoQ = -9.92% (prev -65.81%)
Tobins Q-Ratio = 2.55 (Enterprise Value 751.0m / Total Assets 294.7m)
Interest Expense / Debt = 1.38% (Interest Expense 74.0k / Debt 5.34m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -74.8m (EBIT -94.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 20.93 (Total Current Assets 286.7m / Total Current Liabilities 13.7m)
Debt / Equity = 0.02 (Debt 5.34m / totalStockholderEquity, last quarter 278.4m)
Debt / EBITDA = 2.99 (negative EBITDA) (Net Debt -277.9m / EBITDA -92.9m)
Debt / FCF = 3.21 (negative FCF - burning cash) (Net Debt -277.9m / FCF TTM -86.7m)
Total Stockholder Equity = 76.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -53.92% (Net Income -95.3m / Total Assets 294.7m)
RoE = -124.4% (Net Income TTM -95.3m / Total Stockholder Equity 76.6m)
RoCE = -119.7% (out of range, set to none) (EBIT -94.6m / Capital Employed (Equity 76.6m + L.T.Debt 2.42m))
RoIC = -26.49% (negative operating profit) (NOPAT -74.8m / Invested Capital 282.2m)
WACC = 12.40% (E(1.03b)/V(1.03b) * Re(12.46%) + D(5.34m)/V(1.03b) * Rd(1.38%) * (1-Tc(0.21)))
Discount Rate = 12.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -73.03 | Cagr: -17.09%
[DCF] Fair Price = unknown (Cash Flow -86.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: -88.01 | Revenue CAGR: -16.36% | SUE: -0.48 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.21 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.25 | Chg30d=+0.00% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.08 | Chg30d=+0.00% | Revisions=-17% | GrowthEPS=+57.6% | GrowthRev=+414.6%
EPS next Year (2027-12-31): EPS=-0.98 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=+9.3% | GrowthRev=+43.8%
[Analyst] Revisions Ratio: +0% (up=5, down=5)